Pharmacokinetic Research Laboratories , Ono Pharmaceutical Co., Ltd. , Ibaraki , Japan.
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences , Kumamoto University , Kumamoto , Japan.
Mol Pharm. 2019 Oct 7;16(10):4131-4138. doi: 10.1021/acs.molpharmaceut.9b00435. Epub 2019 Aug 28.
ONO-2160 is a newly developed oral ester-type prodrug of levodopa for removing the problems in use of levodopa. It has a structure in which two of the same substituents are bound to levodopa. It is important to understand the pharmacokinetics and metabolic pathway for new drug candidate compounds. The aim of this study was to identify the major enzymes that contribute to the metabolism of ONO-2160 in human plasma. ONO-2160 was hydrolyzed by human serum albumin (HSA) and α-acid glycoprotein (AGP) in human plasma, although the hydrolysis was not inhibited by various reported esterase inhibitors. The value of the intrinsic clearance per milliliter of plasma of ONO-2160 in AGP solution was greater than that in HSA solution and was comparable to that in human plasma. Therefore, AGP is responsible for the hydrolysis of ONO-2160 in human plasma. ONO-M, which is an intermediate metabolite of ONO-2160, has a structure in which one substituent is removed from ONO-2160 and was mainly generated in AGP solution, but not in human plasma or HSA solution. The hydrolysis of ONO-M by HSA was much greater than by AGP. These results indicate that ONO-M, which is mainly generated from ONO-2160 by AGP, is rapidly hydrolyzed by HSA, and that ONO-2160 generates levodopa via ONO-M in a relay-type reaction through AGP and HSA in human plasma. It has not been reported that AGP has esterase-like activity. These findings could be useful information for drug development of the ester-type prodrug.
ONO-2160 是一种新开发的左旋多巴口服酯型前药,用于解决左旋多巴使用中的问题。它的结构是两个相同的取代基与左旋多巴结合。了解新药候选化合物的药代动力学和代谢途径非常重要。本研究的目的是确定参与人血浆中 ONO-2160 代谢的主要酶。ONO-2160 在人血浆中被人血清白蛋白 (HSA) 和α-酸性糖蛋白 (AGP) 水解,尽管水解不受各种报道的酯酶抑制剂的抑制。AGP 溶液中 ONO-2160 的每毫升血浆固有清除率的值大于 HSA 溶液中的值,并且与人类血浆中的值相当。因此,AGP 负责人血浆中 ONO-2160 的水解。ONO-M 是 ONO-2160 的中间代谢物,其结构是从 ONO-2160 中去除一个取代基,主要在 AGP 溶液中生成,但不在人血浆或 HSA 溶液中生成。HSA 对 ONO-M 的水解作用远大于 AGP。这些结果表明,主要由 AGP 从 ONO-2160 生成的 ONO-M 被 HSA 迅速水解,并且 ONO-2160 通过 AGP 和 HSA 在人血浆中以接力式反应生成左旋多巴。尚未报道 AGP 具有酯酶样活性。这些发现可为酯型前药的药物开发提供有用信息。